Accetto 1982.

Methods	Study design: double‐blinded, randomised Country: Yugoslavia Setting: single centre Intention‐to‐treat: no
Participants	Number of participants randomly assigned: 60 Number of participants analysed: 47 (23 pentoxifylline, 24 nylidrin HCL) Exclusions post randomisation: 13 Losses to follow‐up: none Age: mean 61 years (range 30 to 80 years) Sex: 36 male, 14 female Inclusion criteria: Fontaine stage II or III; initial claudication distance > 50 m and < 500 m at 3 km/h at 0 degrees of inclination; severity of disorder unchanged for 6 months Exclusion criteria: advanced limb arterial occlusion; peripheral venous disorders; systemic haematological disorders; severely impaired renal function; GI disorders; hypersensitivities to methylxanthines; women of childbearing age; taking cardiac medication, glycosides and antihypertensives or antibiotics < 4 weeks before the study
Interventions	Treatment: oral pentoxifylline, 400 mg 3 times daily Control: nylidrin HCl, 3 mg 3 times daily Duration: 8 weeks
Outcomes	Primary: mean TWD Secondary: side effects
Notes	Treadmill protocol: 3 km/h without inclination Mean TWD stated in metres and seconds
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not mentioned
Allocation concealment (selection bias)	Unclear risk	Not mentioned
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Reports 'double blinded'; no other information available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not mentioned
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Reasons for withdrawals not provided
Selective reporting (reporting bias)	Unclear risk	Protocol not available; insufficient information available to permit judgement
Other bias	Low risk	Study appears free of other bias